Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, randomized, double-blind, placebo-controlled, single bolus, multinational, multi-center, parallel group, dose-ranging study of desmoteplase (INN) in the indication of acute stroke.

Next Previous
X
Search
Trial Profile

A prospective, randomized, double-blind, placebo-controlled, single bolus, multinational, multi-center, parallel group, dose-ranging study of desmoteplase (INN) in the indication of acute stroke.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Desmoteplase (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms DIAS-2

    • Most Recent Events

    • 19 Aug 2011 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
    • 25 Feb 2010 The findings from the post hoc analysis provided the basis for the design of the currently ongoing clinical phase III programme (DIAS-3 and -4).
    • 25 Feb 2010 Data from a post-hoc subgroup analysis have been presented at the International Stroke Conference (ISC), according to a Lundbeck media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top